221 related articles for article (PubMed ID: 31121035)
1. Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Zhao SG; Yu M; Spratt DE; Chang SL; Feng FY; Kim MM; Speers CW; Carlson BL; Mladek AC; Lawrence TS; Sarkaria JN; Wahl DR
Neuro Oncol; 2019 Sep; 21(9):1141-1149. PubMed ID: 31121035
[TBL] [Abstract][Full Text] [Related]
2. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
3. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
[TBL] [Abstract][Full Text] [Related]
4. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Vaubel RA; Tian S; Remonde D; Schroeder MA; Mladek AC; Kitange GJ; Caron A; Kollmeyer TM; Grove R; Peng S; Carlson BL; Ma DJ; Sarkar G; Evers L; Decker PA; Yan H; Dhruv HD; Berens ME; Wang Q; Marin BM; Klee EW; Califano A; LaChance DH; Eckel-Passow JE; Verhaak RG; Sulman EP; Burns TC; Meyer FB; O'Neill BP; Tran NL; Giannini C; Jenkins RB; Parney IF; Sarkaria JN
Clin Cancer Res; 2020 Mar; 26(5):1094-1104. PubMed ID: 31852831
[TBL] [Abstract][Full Text] [Related]
5. Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.
Wang T; Pham A; Yoo S; Attenello FJ; Jennelle R; Wagle N; Chang EL; Zada G
World Neurosurg; 2020 May; 137():e213-e220. PubMed ID: 32001415
[TBL] [Abstract][Full Text] [Related]
6. The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.
Kamson DO; Grossman SA
JAMA Oncol; 2021 May; 7(5):675-676. PubMed ID: 33475680
[No Abstract] [Full Text] [Related]
7. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
8. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
9. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
10. How I treat glioblastoma in older patients.
Mohile NA
J Geriatr Oncol; 2016 Jan; 7(1):1-6. PubMed ID: 26725536
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
[TBL] [Abstract][Full Text] [Related]
12. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
[TBL] [Abstract][Full Text] [Related]
13. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Tunthanathip T; Sangkhathat S
Clin Neurol Neurosurg; 2020 Apr; 191():105712. PubMed ID: 32036239
[TBL] [Abstract][Full Text] [Related]
16. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Glioblastoma.
Nam JY; de Groot JF
J Oncol Pract; 2017 Oct; 13(10):629-638. PubMed ID: 29020535
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
20. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
